Autolus Therapeutics annual net debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Autolus Therapeutics Net Debt Growth & History (AUTL)
Autolus Therapeutics's net debt was −$32.7M for fiscal 2025.
View full Autolus Therapeutics company overviewAutolus Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$32.7M | $142.0M | — |
| 2024 | 2024-12-31 | −$174.8M | $11.8M | — |
| 2023 | 2023-12-31 | −$186.6M | $171.6M | — |
| 2022 | 2022-12-31 | −$358.2M | −$68.8M | — |
| 2021 | 2021-12-31 | −$289.3M | −$189.4M | — |
| 2020 | 2020-12-31 | −$99.9M | $85.3M | — |
| 2019 | 2019-12-31 | −$185.2M | — | — |
| 2018 | 2018-09-30 | −$246.7M | −$110.4M | — |
| 2017 · Sep 30 | 2017-09-30 | −$136.3M | — | — |
Autolus Therapeutics quarterly net debt
Q4.18
Q1.19
Q3.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q4.21
Q4.22
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$87.9M | −$28.6M | — |
| Q1 2026 | 2026-03-31 | −$51.0M | −$12.9M | — |
| Q4 2025 | 2025-12-31 | −$32.7M | $142.0M | — |
| Q3 2025 | 2025-09-30 | −$20.3M | $584.5M | — |
| Q2 2025 | 2025-06-30 | −$59.3M | $596.6M | — |
| Q1 2025 | 2025-03-31 | −$38.1M | $669.1M | — |
| Q4 2024 | 2024-12-31 | −$174.8M | $11.8M | — |
| Q3 2024 | 2024-09-30 | −$604.8M | −$400.9M | — |
| Q2 2024 | 2024-06-30 | −$655.9M | — | — |
| Q1 2024 | 2024-03-31 | −$707.2M | — | — |
| Q4 2023 | 2023-12-31 | −$186.6M | $171.6M | — |
| Q3 2023 | 2023-09-30 | −$204.0M | — | — |
| Q4 2022 | 2022-12-31 | −$358.2M | −$68.8M | — |
| Q4 2021 | 2021-12-31 | −$289.3M | −$189.4M | — |
| Q1 2021 | 2021-03-31 | −$216.6M | $879,000 | — |
| Q4 2020 | 2020-12-31 | −$99.9M | $85.3M | — |
| Q3 2020 | 2020-09-30 | −$125.6M | $77.7M | — |
| Q2 2020 | 2020-06-30 | −$184.6M | $54.7M | — |
| Q1 2020 | 2020-03-31 | −$217.4M | — | — |
| Q4 2019 | 2019-12-31 | −$185.2M | $32.1M | — |
| Q3 2019 · Sep 30 | 2019-09-30 | −$203.3M | $43.4M | — |
| Q3 2019 · Jun 30 | 2019-06-30 | −$239.3M | — | — |
| Q1 2019 | 2018-12-31 | −$217.3M | — | — |
| Q4 2018 | 2018-09-30 | −$246.7M | — | — |
Autolus Therapeutics net debt trends
Over the last five fiscal years, Autolus Therapeutics's net debt increased from −$99.9M to −$32.7M, a change of $67.2M. The latest reported quarter, Q2 2026, shows −$87.9M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Autolus Therapeutics source filings ↗